Abstract Library

#2089 Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Patients with GEP-NETs

Introduction: The majority of patients diagnosed with gastroenteropancreatic (GEP)-NETs present metastases expressing somatostatin receptor 2 (SSTR2). The 68Gallium-labelled SSTR2 antagonist 68Ga-OPS202 has shown improved diagnostic performance as a PET imaging agent compared with the SSTR2 agonist 68Ga-DOTA-TOC in a single-centre study.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Virgolini I, Brouwers A, Haug A, Grønbæk H, Kjær A,

Keywords: 68Ga-OPS202, GEP-NET, SSTR2, optimal dose range,

#1529 Somatostatin Receptor PET/CT with Radiolabelled Antagonist Is Twice as Effective as the Agonist for Detecting Liver Metastases: Results of a Phase 1/2 Study Comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT in Gastroenteropancreatic NET Patients

Introduction: 68Ga-DOTATOC PET/CT is a reference method for imaging somatostatin receptor (sstr) expressing neuroendocrine tumors (NET). Presence and extent of liver metastases impact on patient management and prognosis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Nicolas G

Authors: Nicolas G, Schreiter N, Kaul F, Uiters J, Mena R,

Keywords: Radiolabelled somatostatin antagonist, PET, GEP-NET,

#1324 Somatostatin receptor PET/CT with radiolabelled antagonist is twice as effective as the agonist for detecting liver metastases: Results of a phase I/II study comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT in gastro-entero-pancreatic neuroendocrine tumor p

Introduction: 68Ga-DOTATOC PET/CT is a reference method for imaging somatostatin receptor (sst) expressing tumors (NET). Presence of liver metastases impacts on patient management and prognosis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Nicolas G

Authors: Nicolas G, Schreiter N, Kaul F, Uiters J, Mena R,

Keywords: somatostatin antagonist, PET,